ECSP20084330A - Activadores de la respuesta a proteínas desplegadas - Google Patents
Activadores de la respuesta a proteínas desplegadasInfo
- Publication number
- ECSP20084330A ECSP20084330A ECSENADI202084330A ECDI202084330A ECSP20084330A EC SP20084330 A ECSP20084330 A EC SP20084330A EC SENADI202084330 A ECSENADI202084330 A EC SENADI202084330A EC DI202084330 A ECDI202084330 A EC DI202084330A EC SP20084330 A ECSP20084330 A EC SP20084330A
- Authority
- EC
- Ecuador
- Prior art keywords
- cancer cells
- square
- kill
- therapy
- activators
- Prior art date
Links
- 239000012190 activator Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 206010006187 Breast cancer Diseases 0.000 abstract 2
- 208000026310 Breast neoplasm Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 abstract 2
- 150000003384 small molecules Chemical class 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- FABLAHMQSQFDHR-UHFFFAOYSA-N 3,3-bis(4-hydroxyphenyl)-7-methyl-1h-indol-2-one Chemical compound CC1=CC=CC2=C1NC(=O)C2(C=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 FABLAHMQSQFDHR-UHFFFAOYSA-N 0.000 abstract 1
- 206010014733 Endometrial cancer Diseases 0.000 abstract 1
- 206010014759 Endometrial neoplasm Diseases 0.000 abstract 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000011443 conventional therapy Methods 0.000 abstract 1
- 238000009261 endocrine therapy Methods 0.000 abstract 1
- 229960002258 fulvestrant Drugs 0.000 abstract 1
- 239000000367 immunologic factor Substances 0.000 abstract 1
- 230000002611 ovarian Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 229960001603 tamoxifen Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Conjunto de biomoduladores ER (figura cuadrada) de moléculas pequeñas que destruyen las células cancerosas de mama, ovario y endometrio ER (figura cuadrada) positivas resistentes a la terapia. Estas pequeñas moléculas tienen un mayor potencial terapéutico debido a la mayor capacidad para destruir las células de cáncer de mama resistentes a la terapia en comparación con BHPI y otras terapias convencionales (terapias endocrinas, tamoxifeno y fulvestrant/ICI). Los nuevos compuestos no solo inhiben la proliferación de las células cancerosas, sino que también realmente las destruye, lo que evita la reactivación de los tumores años después.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862693641P | 2018-07-03 | 2018-07-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP20084330A true ECSP20084330A (es) | 2021-01-29 |
Family
ID=69059783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202084330A ECSP20084330A (es) | 2018-07-03 | 2020-12-29 | Activadores de la respuesta a proteínas desplegadas |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US12180159B2 (es) |
| EP (1) | EP3817741A4 (es) |
| JP (1) | JP2021529757A (es) |
| KR (1) | KR20210027382A (es) |
| CN (1) | CN112423743A (es) |
| AU (1) | AU2019299221A1 (es) |
| BR (1) | BR112020025591A2 (es) |
| CA (1) | CA3103958A1 (es) |
| CL (1) | CL2020003423A1 (es) |
| CO (1) | CO2020016690A2 (es) |
| CR (1) | CR20210060A (es) |
| DO (1) | DOP2020000256A (es) |
| EA (1) | EA202190146A1 (es) |
| EC (1) | ECSP20084330A (es) |
| IL (1) | IL279429A (es) |
| JO (1) | JOP20200344A1 (es) |
| MA (1) | MA53105A (es) |
| MX (1) | MX2021000043A (es) |
| PE (1) | PE20210662A1 (es) |
| PH (1) | PH12020552223A1 (es) |
| SG (1) | SG11202012902WA (es) |
| WO (1) | WO2020009958A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021529757A (ja) | 2018-07-03 | 2021-11-04 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ | 小胞体ストレス応答の活性剤 |
| WO2021222738A1 (en) * | 2020-05-01 | 2021-11-04 | The Board Of Trustees Of The University Of Illinois | Compounds for estrogen receptor positive cancers |
| WO2022020605A1 (en) * | 2020-07-23 | 2022-01-27 | The Board Of Trustees Of The University Of Illinois | Treatment of metastasized estrogen receptor positive breast cancer |
| WO2022032146A1 (en) * | 2020-08-07 | 2022-02-10 | Systems Oncology, Llc | Methods for inhibiting growth of era positive cancers |
| JP2023546584A (ja) * | 2020-10-23 | 2023-11-06 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシテイ オブ イリノイ | Ｅｒ陽性がんに選択的な抗がん化合物 |
| CN120981469A (zh) * | 2023-02-23 | 2025-11-18 | 晨晖生物科技(香港)有限公司 | 含硼化合物及其治疗用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003078394A1 (en) | 2002-03-15 | 2003-09-25 | Eli Lilly And Company | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators |
| US20050070718A1 (en) | 2003-09-30 | 2005-03-31 | Abbott Gmbh & Co. Kg | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
| JP4989976B2 (ja) | 2004-02-13 | 2012-08-01 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | 翻訳開始阻害剤としての３−３−二置換オキシインドール |
| US7517899B2 (en) | 2004-03-30 | 2009-04-14 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
| US20070299102A1 (en) | 2004-04-08 | 2007-12-27 | Topo Target A/S | Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer |
| BRPI0616459A2 (pt) | 2005-09-29 | 2011-06-21 | Wyeth Corp | compostos das fórmulas i, ii, e iii; processos para o tratamento ou para a prevenção de: um estado de saúde com melhora devido à recaptação de monoamina; pelo menos um sintoma vasomotor; pelo menos um distúrbio depressivo; pelo menos uma disfunção sexual; para a prevenção de dor; de distúrbio gastrointestinal ou genitourinário; de sìndrome de fadiga crÈnica; de sìndrome de fibromialgia; de esquizofrenia; e uso de um composto |
| PE20080655A1 (es) | 2006-08-24 | 2008-07-14 | Wyeth Corp | Proceso para preparar derivados de indolinona fenilaminopropanol |
| WO2008071387A1 (en) * | 2006-12-11 | 2008-06-19 | Topotarget A/S | Prodrugs of diphenyl ox- indol- 2 -one compounds for the treatment of cancers |
| JP2010525024A (ja) | 2007-04-24 | 2010-07-22 | トポターゲット・アクティーゼルスカブ | 置換３−（４−ヒドロキシフェニル）−インドリン−２−オン化合物 |
| MX2009013332A (es) | 2007-06-08 | 2010-01-25 | Mannkind Corp | Inhibidores de ire-1 alfa. |
| WO2010109008A1 (en) | 2009-03-26 | 2010-09-30 | Topotarget A/S | Prodrugs of substituted 3-(4-hydroxyphenyl)-indolin-2-ones |
| WO2014047437A1 (en) | 2012-09-20 | 2014-03-27 | President And Fellows Of Harvard College | 3-3-di-substituted-oxindoles as inhibitors of translation initiation |
| US9316631B1 (en) | 2012-10-19 | 2016-04-19 | Whitehead Institute For Biomedical Research | ER-stress inducing compounds and methods of use thereof |
| CA2898732A1 (en) | 2013-01-18 | 2014-07-24 | Mao CHENGJIAN | Estrogen receptor inhibitors |
| JP6806562B2 (ja) | 2013-03-15 | 2021-01-06 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ｅＩＦ２α経路の調節因子 |
| UY35590A (es) | 2013-05-28 | 2014-11-28 | Astrazeneca Ab | Nuevos compuestos para el tratamiento del cáncer |
| JP2021529757A (ja) | 2018-07-03 | 2021-11-04 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ | 小胞体ストレス応答の活性剤 |
-
2019
- 2019-07-01 JP JP2020573046A patent/JP2021529757A/ja active Pending
- 2019-07-01 SG SG11202012902WA patent/SG11202012902WA/en unknown
- 2019-07-01 CA CA3103958A patent/CA3103958A1/en not_active Abandoned
- 2019-07-01 KR KR1020217001833A patent/KR20210027382A/ko not_active Withdrawn
- 2019-07-01 EP EP19831532.7A patent/EP3817741A4/en not_active Withdrawn
- 2019-07-01 MA MA053105A patent/MA53105A/fr unknown
- 2019-07-01 CR CR20210060A patent/CR20210060A/es unknown
- 2019-07-01 CN CN201980045131.2A patent/CN112423743A/zh active Pending
- 2019-07-01 JO JOP/2020/0344A patent/JOP20200344A1/ar unknown
- 2019-07-01 US US17/254,771 patent/US12180159B2/en active Active
- 2019-07-01 PE PE2020002206A patent/PE20210662A1/es unknown
- 2019-07-01 AU AU2019299221A patent/AU2019299221A1/en not_active Abandoned
- 2019-07-01 BR BR112020025591-2A patent/BR112020025591A2/pt not_active IP Right Cessation
- 2019-07-01 MX MX2021000043A patent/MX2021000043A/es unknown
- 2019-07-01 WO PCT/US2019/040058 patent/WO2020009958A1/en not_active Ceased
- 2019-07-01 EA EA202190146A patent/EA202190146A1/ru unknown
-
2020
- 2020-02-26 US US16/801,839 patent/US11046647B2/en active Active
- 2020-12-14 IL IL279429A patent/IL279429A/en unknown
- 2020-12-19 PH PH12020552223A patent/PH12020552223A1/en unknown
- 2020-12-29 DO DO2020000256A patent/DOP2020000256A/es unknown
- 2020-12-29 EC ECSENADI202084330A patent/ECSP20084330A/es unknown
- 2020-12-29 CL CL2020003423A patent/CL2020003423A1/es unknown
- 2020-12-30 CO CONC2020/0016690A patent/CO2020016690A2/es unknown
-
2021
- 2021-05-13 US US17/319,447 patent/US11584718B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020025591A2 (pt) | 2021-03-23 |
| US11584718B2 (en) | 2023-02-21 |
| MX2021000043A (es) | 2021-03-25 |
| CL2020003423A1 (es) | 2021-05-14 |
| AU2019299221A1 (en) | 2021-02-04 |
| IL279429A (en) | 2021-01-31 |
| JOP20200344A1 (ar) | 2020-12-31 |
| EP3817741A4 (en) | 2022-07-06 |
| CA3103958A1 (en) | 2020-01-09 |
| DOP2020000256A (es) | 2021-03-15 |
| US12180159B2 (en) | 2024-12-31 |
| KR20210027382A (ko) | 2021-03-10 |
| MA53105A (fr) | 2021-05-12 |
| US20210276951A1 (en) | 2021-09-09 |
| CO2020016690A2 (es) | 2021-01-18 |
| US11046647B2 (en) | 2021-06-29 |
| JP2021529757A (ja) | 2021-11-04 |
| SG11202012902WA (en) | 2021-01-28 |
| US20210340100A1 (en) | 2021-11-04 |
| WO2020009958A1 (en) | 2020-01-09 |
| CR20210060A (es) | 2021-04-08 |
| EP3817741A1 (en) | 2021-05-12 |
| PH12020552223A1 (en) | 2021-06-28 |
| US20200190029A1 (en) | 2020-06-18 |
| PE20210662A1 (es) | 2021-03-31 |
| CN112423743A (zh) | 2021-02-26 |
| EA202190146A1 (ru) | 2021-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20084330A (es) | Activadores de la respuesta a proteínas desplegadas | |
| AR110728A1 (es) | Terapia combinada para el tratamiento del cáncer | |
| CO2020009091A2 (es) | Exosomas para inmunooncología y terapia antiinflamatoria | |
| MX2021007158A (es) | Heteroarilamidas utiles como inhibidores de kif18a. | |
| UY38236A (es) | COMBINACIONES FARMACÉUTICAS QUE CONTIENEN EL ANTICUERPO ANTI-CD38, ASOCIADO CON LOS ANTICUERPOS BIOESPECÍFICOS BCMAxCD3 O GPRC5DxCD3 O CD19xCD3 | |
| CL2018002683A1 (es) | Antígeno prostático específico de membrana dirigido a agentes de alta afinidad para la endo radio terapia del cáncer de próstata | |
| CO2021008224A2 (es) | Inhibidores de kif18a | |
| CO2020013252A2 (es) | Dosificación subcutánea de anticuerpos anti-cd38 | |
| CO2020008561A2 (es) | Dosificación subcutánea de anticuerpos anti-cd38 | |
| MX2021001510A (es) | Proteínas de union a nkg2d, cd16, y un antígeno asociado a tumores. | |
| MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
| CL2020001797A1 (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas. | |
| MX2016010519A (es) | Moleculas para administracion a celulas cancerosas mutantes ros1. | |
| MX2019014021A (es) | Derivado de n-(azaarilo)ciclo lactam-1-carboxamida, metodo de preparacion del mismo y uso del mismo. | |
| MX2023000677A (es) | Compuestos moduladores de receptor de estrogeno. | |
| SV2017005411A (es) | Compuestos de aminopiridiloxipirazol | |
| EA201891526A3 (ru) | Ингибиторы лизин-специфической деметилазы-1 | |
| CO2021000049A2 (es) | Inhibidores de ectonucleotidasa y métodos de uso de los mismos | |
| MX2020005640A (es) | Anticuerpos anti-liv1 humanizados para el tratamiento de cancer de mama. | |
| GT201000172A (es) | Inhibidores de cinesina como productos terapéuticos para el cáncer | |
| CL2021001593A1 (es) | Tubulisinas y conjugados de proteína-tubulisina | |
| BR112018015749A2 (pt) | ativador de fármaco contendo fósforo, suspensão de um ativador de fármaco contendo fósforo, e, sistema e método para tratamento de uma doença. | |
| CL2025000272A1 (es) | Derivados de arilo tricíclico y composiciones y métodos de los mismos | |
| MX2022005250A (es) | Combinaciones terapeuticas de acalabrutinib y capivasertib para tratar neoplasias malignas de linfocitos b. | |
| MX2021005189A (es) | Uso de tivozanib para tratar sujetos con cancer refractario. |